276 related articles for article (PubMed ID: 12082526)
1. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Stein T; Crighton D; Boyle JM; Varley JM; White RJ
Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
3. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
[TBL] [Abstract][Full Text] [Related]
4. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
5. p53 is a general repressor of RNA polymerase III transcription.
Cairns CA; White RJ
EMBO J; 1998 Jun; 17(11):3112-23. PubMed ID: 9606193
[TBL] [Abstract][Full Text] [Related]
6. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
7. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
8. Several regions of p53 are involved in repression of RNA polymerase III transcription.
Stein T; Crighton D; Warnock LJ; Milner J; White RJ
Oncogene; 2002 Aug; 21(36):5540-7. PubMed ID: 12165852
[TBL] [Abstract][Full Text] [Related]
9. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
10. Two Li-Fraumeni syndrome families with novel germline p53 mutations: loss of the wild-type p53 allele in only 50% of tumours.
Sedlacek Z; Kodet R; Kriz V; Seemanova E; Vodvarka P; Wilgenbus P; Mares J; Poustka A; Goetz P
Br J Cancer; 1998 Apr; 77(7):1034-9. PubMed ID: 9569035
[TBL] [Abstract][Full Text] [Related]
11. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
12. The Li-Fraumeni syndrome: an inherited susceptibility to cancer.
Evans SC; Lozano G
Mol Med Today; 1997 Sep; 3(9):390-5. PubMed ID: 9302689
[TBL] [Abstract][Full Text] [Related]
13. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
Gu J; Kawai H; Wiederschain D; Yuan ZM
Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
[TBL] [Abstract][Full Text] [Related]
15. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility.
Akashi M; Koeffler HP
Clin Obstet Gynecol; 1998 Mar; 41(1):172-99. PubMed ID: 9504235
[TBL] [Abstract][Full Text] [Related]
16. Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function.
Marston NJ; Crook T; Vousden KH
Oncogene; 1994 Sep; 9(9):2707-16. PubMed ID: 8058335
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
18. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53.
Birch JM; Heighway J; Teare MD; Kelsey AM; Hartley AL; Tricker KJ; Crowther D; Lane DP; Santibáñez-Koref MF
Br J Cancer; 1994 Dec; 70(6):1176-81. PubMed ID: 7981072
[TBL] [Abstract][Full Text] [Related]
19. Repression of RNA polymerase III transcription by the retinoblastoma protein.
White RJ; Trouche D; Martin K; Jackson SP; Kouzarides T
Nature; 1996 Jul; 382(6586):88-90. PubMed ID: 8657311
[TBL] [Abstract][Full Text] [Related]
20. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
